a year ago

MIP Discovery Secures £7 Million Series A Funding for Cell and Gene Therapy Advancements

  • MIP Discovery, a UK-based developer of non-biological affinity reagents for cell and gene therapies, has raised £7 million in Series A funding led by Mercia Ventures

  • Existing investor Calculus Capital and angel investors also participated

  • The funding will be used to drive commercialisation of MIP Discovery's novel synthetic affinity reagents within the cell and gene therapy space and support recruitment efforts to expand in-house cell and gene therapy expertise.

      • ProblemHealthcare

      "developing non-biological affinity reagents for cell and gene therapies"

      Solution

      "designing synthetic antibody alternatives to accelerate development and production of cell and gene therapies"

      Covered on